(Q34604733)

3 August 2017

YMDD mutations in patients with chronic hepatitis B untreated with antiviral medicines (English)

1 reference

3 August 2017

1 reference

1 reference

Zhong-Min Huang

1

1 reference

3 August 2017

Qi-Wen Huang

2

1 reference

3 August 2017

Ya-Qin Qin

3

1 reference

3 August 2017

Yan-Zhuan He

4

1 reference

3 August 2017

Hou-Ji Qin

5

1 reference

3 August 2017

Yiao-Nan Zhou

6

1 reference

3 August 2017

Xiang Xu

7

1 reference

3 August 2017

Mei-Jin Huang

8

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 February 2005

1 reference

World Journal of Gastroenterology

3 August 2017

1 reference

3 August 2017

11

1 reference

3 August 2017

6

1 reference

3 August 2017

867-870

1 reference

Results of lamivudine trials in Asia

3 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250599

Experience with lamivudine therapy for hepatitis B virus infection before and after liver transplantation, and review of the literature

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250599

Management of viral hepatitis B.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250599

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250599

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250599

Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250599

Severe acute exacerbation of liver disease may reduce or delay emergence of YMDD motif mutants in long-term lamivudine therapy for hepatitis B e antigen-positive chronic hepatitis B.

7 July 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V11.I6.867

Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V11.I6.867

Genotypic and phenotypic resistance: longitudinal and sequential analysis of hepatitis B virus polymerase mutations in patients with lamivudine resistance after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V11.I6.867

Fatal hepatic failure after emergence of the hepatitis B virus mutant during lamivudine therapy in a patient with liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V11.I6.867

Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V11.I6.867

Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V11.I6.867

Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V11.I6.867

Low rate of YMDD motif mutations in polymerase gene of hepatitis B virus in chronically infected patients not treated with lamivudine.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V11.I6.867

Recent progress and new trends in the treatment of hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V11.I6.867

Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V11.I6.867

Emergence and clinical significance of YMDD and HBeAg-related mutations during lamivudine treatment

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250599

Clinical characteristics of asymptomatic hepatitis B virus carriers with YMDD mutant not treated with lamivudine

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250599

Effect of interferon combined with lamivudine in treatment of chronic hepatitis B patients infected with HBV with mutation of YMDD

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250599

Individual therapy for the patients with YMDD mutation in HBV by lamivudine

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250599

The long-term efficacy of lamivudine in chronic hepatitis B: interim analysis of 3-year's clinical course

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250599

Detection of YMDD motif mutations in lamivudine-untreated patients with chronic hepatitis B

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250599

Evaluation of different methods in monitoring YMDD motif mutations associated with lamivudine resistance

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250599

[Study of gene chips in the detection of YMDD mutations in the region of HBV polymeras].

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250599

Therapeutic efficacy of combined application of lamivudine and bushen recipe in treating chronic hepatitis B and its influence on YMDD motif

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250599

Clinical study of oligonucleotide microarray on monitoring the lamivudine-resistance mutations in hepatitis B virus

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250599

Therapy effect of lamivudine combination with alpha interferon on patients with chronic hepatitis B

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250599

Development of peptide nucleic acid mediated polymerase chain reaction clamping (PMPC)--direct sequencing method for detecting lamivudine-resistant hepatitis B virus (HBV) variants with high sensitivity and specificity

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250599

Predictive factors for response to lamivudine in chronic hepatitis B.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250599

[Long-term effect of lamivudine treatment in chronic hepatitis B virus infection]

26 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/15682483

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

HBV genotypic resistance to lamivudine in kidney recipients and hemodialyzed patients

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/15682483

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.3748/WJG.V11.I6.867

1 reference

3 August 2017

1 reference

3 August 2017

1 reference